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A B S T R A C T
Radiofrequency ablation (RFA) is one treatment modality for unresectable liver metastases. Patients with hepatic ma-
lignancies (n=24) underwent elective RFA. All tumors were ablated with a curative intent, with a margin of 1 cm, in a
single session of RFA. The median diameter of tumor was 3.1 cm (range 1.7–6.9 cm). Studied patients were not candi-
dates for resection due to multifocal hepatic disease, extrahepatic disease, proximity to major vascular structures or pres-
ence of cirrhosis with functional hepatic reserve inadequate to tolerate major hepatic resection. Complete tumor necrosis
was achieved in 87.5% and tumor recurred in 3 patients (12.5%) with lesions larger than 5 cm. Distant intrahepatic re-
currence was diagnosed in another 4 (16.7%). Distant metastases were found in 7 (29.2%) patients. Four of these 7 pa-
tients had also distant intrahepatic recurrence of disease. Two and 5-years survival rates were 41.7% (10 patients) and
8.3% (2 patients) respectively. RFA is safe and effective option for patients with unresectable hepatic malignancies
smaller than 5 cm without distant metastatic disease. RF ablation resulted in complete tumor necrosis in 87.5% with 2
and 5-years survival rates much higher than with chemotherapy alone or only supportive therapy, when survival is mea-
sured in weeks or months. If RFA is unavailable, percutaneous ethanol injection therapy can be done but with inferior
survival rates.
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Introduction
Metastasis is the most common neoplasm in an adult
liver, and the liver is the second most common site for
metastatic spread, after the lymph nodes. Analyzing the
data from 9,700 consecutive autopsies in patients with
10,736 primary cancers, Pickren et al found that liver
metastases were present in 41%1. They found that the
primary sites most commonly metastasizing to the liver
are the eye (77.8%), pancreas (75.1%), breast (60.6%),
gallbladder and extrahepatic bile ducts (60.5%), colon or
rectum (56.8%), and stomach (48.9%). Most metastatic
tumors likely arise in the liver as a result of primary
shedding into vascular system2. It is not uncommon,
paricularly in patients with colorectal adenocarcinoma,
for liver to be the only site of metastatic disease. Liver
metastases are synchronously present in 20–30% of pa-
tients undergoing primary resection of colorectal cancer3.
Approximately 60% of colorectal cancer patients will de-
velop metastatic disease, with the liver being the most
common site for metastatic disease4. Previously more pa-
tients were defined as having unresectable metastatic
disease because of factors concentrated on the lesions to
be removed and patient factors rather than the liver that
would remain. These criteria were based on criteria
made by Ekberg et al. which included: four or more
metastases within the liver, additional extrahepatic met-
astatic disease, large size of hepatic metastases, and the
inability to achieve a resection margin of at least 1 cm5.
Today, in an era of better adjuvant therapy and imaging
modalities, survival difference between patients who had
one to three metastases and patients who had four or
more metastases as long as they underwent an R0 (i.e.,
microscopically negative) resection are lacking6. Also
extrahepatic disease should be precisely defined. Direct
tumor extension into extrahepatic region pathophysiolo-
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gically does not present further metastatic potential ra-
ther bigger liver metastasis. Thus, resection of liver me-
tastasis with direct extrahepatic extension has reported
5-year survival rates of 10%7. Despite all these improve-
ments in selection criteria for liver resections huge num-
ber of patients with primary or metastatic hepatic malig-
nancy are not candidates for surgical resection, and an
ablation techniques to control and potentially to cure
liver disease must be used.
One of such ablative techniques is radiofrequency ab-
lation (RFA) which uses energy of 450 to 500 KHz for
hyperthermic ablation of liver tumors. Once cells are
heated above 50 °C, cells membrane melt and fuse, and
with continued heating, protein denaturation and cell
death occurs8,9. Radiofrequency electricity is the type of
electrical energy used in the standard operating room
electrosurgical machines. The size of ablated area is de-
termined largely by current’s intensity and length, the
gauging of electrode tip and the duration of energy
applied10. The current intensity that can be used is lim-
ited by tissue carbonization around needle tip, which can
result in sharp rise in tissue impedance and thus inter-
ruption of the radiofrequency wave flow. This limits the
area of tissue that can be ablated by a single probe. Tis-
sue vascularization is also an important factor that de-
termines the volume of tissue ablated11. Like other heat
ablation methods, complete necrosis of highly vascular
tumors may be impeded by the cooling effect of blood.
The Pringle maneuver during RFA is an effective mea-
sure to reduce the cooling effect of blood12. Another way
to reduce hepatic blood flow is RFA with balloon occlu-
sion of the hepatic artery13. RFA with the conventional
single needle electrode can ablate tumors smaller than 2
cm, but ablating of larger tumors is possible with recent
technical improvements14. The use of expandable elec-
trode with multiple hooks can create overlapping abla-
tion fields up to 7 cm14,15.
Until the introduction of RFA technique for treat-
ment of unresectable liver metastases the patients in
University Hospital Center Zagreb were treated by che-
motherapy and supportive, life-maintaining measures
with death occurring in weeks or months after the diag-
nosis. In this study, we report our initial results in 24 pa-
tients with primary or metastatic hepatic malignancies
treated with RFA of their liver tumors with prolonged
survival rates compared to patients receiving only chemo-
therapy and/or supportive treatment.
Patients and Methods
Patients
Between January 1, 1999, and January 1, 2001, 24 pa-
tients with hepatic malignancies underwent elective RFA
for 32 tumor nodules. There were 15 (62.5%) men and 9
(37.5%) women with median age of 65. Eighteen patients
(75%) had liver metastases from colorectal carcinoma, 3
(12.5%) from breast carcinoma, 1 (4.2%) from lung carci-
noma and 2 (8.3%) had hepatocellular carcinoma. All pa-
tients except patients with hepatocellular carcinoma un-
derwent surgical therapy for primary lesions. Seventeen
patients (70.8%) underwent ablation of a solitary tumor,
5 patients (20.8%) underwent ablation of 2 tumors and 3
patients (8.4%) received ablation of 3 tumors in a single
session of RFA. Two patients with hepatocellular carci-
noma had underlying cirrhosis. None of our patients had
previous hepatic resection or transarterial chemoembo-
lization. All patients received chemotherapy according to
the type of primary tumor. We aimed at ablation of all tu-
mors with a curative intent, with a margin of 1 cm, in a
single session of RFA. The median diameter of tumor was
3.1 cm (range 1.7–6.9 cm). Studied patients were not can-
didates for resectional therapy due to multifocal hepatic
disease, extrahepatic disease, proximity to major vascu-
lar structures or presence of cirrhosis with functional
hepatic reserve inadequate to tolerate major hepatic re-
section.
All patients underwent baseline evaluation including
history and physical examination, serum laboratory tests
consisting of complete blood count, platelets, coagulo-
gram profile, renal panel, electrolytes, albumin, total bil-
irubin, alkaline-phosphatase (ALP), alanine aminotrans-
verase (ALT), aspartate aminotransverase (AST), serum
tumor markers such as alpha-fetoprotein (AFP) and car-
cinoembryonic antigen (CEA) and computed tomography
(CT) of the abdomen.
All patients had histological confirmation of hepatic
malignancy from prior intraoperative biopsy or CT scan
conformation of hepatic lesions. The same battery of se-
rum blood tests and CT of the abdomen were obtained
the day before and after RFA procedure.
Technique of RFA
All our patients were treated surgically during opera-
tive procedure. Intraoperative ultrasonography was used
to locate intraparenchymal lesions and to guide the RFA
needle. Superficial lesions were easily identified and pal-
pated and needle was inserted directly without ultra-
sound. Patients were monitored up to two years after
treatment.
RF ablation was achieved using RF generator RITA
1500 (RITA Medical Systems, Mountain View, CA, USA)
and multiple array needles. Electrode needle is Star-
Burst XL, 14 Gauge, which contains 9 individual hook-
-shaped arms and 5 thermocouples attached to the 15-
-cm-long insulated cannula. Lesions from 3–5 cm could
be ablated with this electrode. Generator could supply up
to 150W of power at 460 kHz with multi-point tempera-
ture feedback and post-ablation conformation of lethal
temperatures.
Depending on the size and site of the tumor, each ab-
lation cycle lasted 8 to 12 minutes. During the procedure,
a needle electrode with an uninsulated tip and an insu-
lated needle shaft is inserted into the tumor. A flux of
high-frequency alternating current passes through the
uninsulated needle tip into the surrounding tissue, gen-
erating rapid vibration of the ions in the tissue and fric-
tional heat11. Tissues are heated not by conduction of
heat directly, but by causing electrons in the tissue to vi-
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brate back and forth at a high frequency. After ablation
of the tumor, the needle track was thermocoagulated by
continuing radiofrequency current in a manual mode
when the needle was withdrawn slowly.
A complication was defined as any adverse event after
RFA, excluding pain or a transient febrile response after
the procedure. Treatment mortality was defined as any
death within 30 days of the RFA treatment. Response to
ablation was assessed by a helical computed tomography
(CT) scan 1 month after ablation. Successful treatment
was encountered when complete ablation was achieved.
Complete ablation is defined as the absence of any con-
trast-enhancing lesion indicating residual tumor at the
ablation site in the postablation CT scan. All patients
had monitoring of serum alpha fetoprotein (AFP) and
carcinoembryonic antigen (CEA) level, chest x-ray, and
CT scan of the abdomen every 3 months to detect intra-
hepatic recurrence or distant metastasis. Local recur-
rence was defined as tumor recurrence within or at the
periphery of the ablated lesion in the subsequent CT
scans after complete ablation was documented in the
first postablation CT scan. Distant intrahepatic recur-
rence was defined as a new tumor that appeared in the
liver separate from the ablated area. Extrahepatic recur-
rence referred to any recurrence outside the liver.
Two year survival rate was defined as the treatment
efficacy for this method and this subpopulation of pa-
tients with unresectable metastatic disease. Also 5-year
survival rate was calculated.
Results
A total of 24 patients have been treated on the RFA
protocol during the study period of 24 months. Follow-up
was 5 years. Intraoperative bleeding from RFA needle
track was noted in 6 patients (25%) of the needle elec-
trode withdrawals. In all cases it was minimal and easily
controlled with cauterization. There have been no deaths
after RFA treatment in these 24 patients. None of the pa-
tients developed renal insufficiency or a coagulopathy af-
ter RFA treatment. The serum liver function tests (AST,
ALT) were elevated for 5 days and returned to baseline
values in all patients by the postoperative day 12.
Response to ablation was assessed by a helical com-
puted tomography (CT) scan 1 month after ablation. Tu-
mor has recurred at the site of RFA in 3 patients (12.5%)
with tumors ³ 5 cm. In other words, complete tumor ne-
crosis was achieved in 87.5% of patients. Distant intrahe-
patic recurrence was diagnosed in another 4 patients
(16.7%). Distant metastases were found in 7 (29.2%) pa-
tients. Four of these 7 patients had also distant intra-
hepatic recurrence of disease.
Serum tumor marker (AFP or CEA) was elevated be-
fore the procedure in 17 patients (70.8%). After RFA in 9
patients, serum tumor markers did not return to baseline
value and 7 of them developed new metastatic lesions.
After 24 months 10 patients were alive (41.7%). Seven
of 14 patients that died in this period were patients with
diagnosed distant metastatic disease. After 5-years only
2 patients were alive (8.3%) and both with primary
colorectal carcinoma.
Discussion
Studies have demonstrated that patients with un-
treated hepatic metastases from colorectal carcinoma
have a 31% survival rate at 1 year, 7.9% at 2 years, 2.6%
at 3 years, and 0.9% at 4 years16,17. Although the median
survival of patients with untreated disease ranges from
6–12 months, the addition of chemotherapy regimens im-
proves median survival to 20 months16.
It must be stressed that surgical resection is the stan-
dard treatment for patients with localized colorectal liver
metastases, with reported 5-year survival rates up to
58%18. Despite the advent of more efficient chemothera-
peutic protocols and the progress in surgical techniques,
such as portal vein embolization, hepatic artery infusion
chemoembolization, cryoablation, microwave coagulation
therapy, laser-induced thermotherapy or hepatectomy,
many patients with hepatic malignancies still have unre-
sectable disease. One of procedures for the treatment of
unresectable hepatic malignancies is RFA. RFA devices
are designed to destroy larger areas of tissue. It can be
performed percutaneously, laparoscopically or through
laparotomy19–27. A percutaneous approach has advantage
that it is minimally invasive and patient may be treated
on an outpatient basis, usually under conscious sedation.
There are, however, limitations to percutaneous approach.
Tumor must be apparent on transabdominal ultraso-
nography to be targeted under ultrasonic guidance. Le-
sions near the dome of the liver are often poorly seen,
and there is concern that treatment of lesions on the pe-
riphery of the liver may damage adjacent viscera. Poor vi-
sualization and respiratory motion may hinder accurate
targeting of lesions such that multiple ablations are of-
ten needed to treat even small tumors19. However, lap-
aroscopic or open approach may be necessary in patients
with high risk of bleeding from severe coagulopathy,
large HCC (³ 5 cm), superficial nodules adjacent to other
visceral organs at risk of thermal injury, or deeply located
lesions not accessible to percutaneous puncture.
A total of 24 patients have been treated on the RFA
protocol during 24 months. All patients underwent open
surgical procedure. That approach allows detection of
peritoneal metastases and extrahepatic invasion that
may not be diagnosed even with extensive preoperative
imaging28. In addition, open procedures allow usage of
intraoperative ultrasound for the detection of small tu-
mor nodules not identified by preoperative imaging. Such
additional nodules are fairly common, as shown in a re-
cent study that identified new tumor lesions in 5 (18.5%)
of 27 patients with HCC 5 cm or smaller undergoing lap-
aroscopic ultrasonography before RFA26. The extent of
the coagulative necrosis is accurately assessed by CT
scan, or MRI. Study demonstrated that almost all treated
lesions increase in size from the preoperative CT scan.
This reflects that tumor, as well as a surrounding rim of
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normal liver tissue, has been ablated. Failure to demon-
strate that increase in size was a risk factor for recurrence.
There have been no early postoperative deaths (within
30 days) after RFA treatment. Complete tumor necrosis
was achieved in 87.5% of patients. Using contrast CT
scan, several studies have shown similar complete tumor
necrosis in 80 to 90% of HCC smaller than 3 to 5 cm after
single session of RFA25,26,29,30. The complete ablation rate
for larger tumors is less favorable: a study of RFA for 126
HCC 3.1 to 9.5 cm reported a complete necrosis rate of
48% even with the use of cluster electrodes. Larger le-
sions are at increased risk for recurrence, perhaps be-
cause of the increased odds of incompletely treating one
surface during multiple overlapping ablations. Also, lar-
ger lesions are seen on ultrasound to be irregular, often
with small satellite lesion at their periphery. This implies
that the actual volume of tumor on a microscopic level
may be larger than it appeared grossly, either on preoper-
ative CT scan, or on laparoscopic ultrasonographic exam-
ination. This could easily explain a greater risk of recur-
rence among larger lesions31. Local tumor recurrence
was evident in 3 patients (12.5%) with tumors larger
than 5 cm. Distant intrahepatic recurrences were diag-
nosed in another 4 (16.7%). These results are similar as
in other studies32. Distant metastases were found in 7
(29.2%) patients. Previous studies have reported highly
variable local recurrence rates associated with RFA,
ranging from 2%27 to 60 %33. Curley et al. reported the
lowest local recurrence rate of 1.8% in one of the largest
series published27. Local recurrences were evident at a
median follow-up time of 6 months and were associated
with ablation of larger tumors. It is possible that the rate
of local recurrence may be reduced by specific interven-
tions. For example, newer probes have been developed to
produce larger spheres of coagulation necrosis. Now we
deploy the electrode in several overlapping ablation sites
to encompass tumors greater than 5 cm in diameter as it
was proposed by others34–36.
After 24 months 10 patients were alive (41.7 %). Sur-
vival rate in our series is is similar to that reported in the
literature18. Seven of 14 patients that died in this period
had distant metastatic disease with primary colorectal
carcinoma. Our results confirm previous conclusions that
patients with distant metastatic disease of colorectal car-
cinoma should be omitted from this protocol because
they do not benefit with RFA procedure. In our series 2
patients with primary colorectal carcinoma with unrese-
ctable hepatic metastases were alive after 5 years (8.3%).
It is lower than in other series such as Siperstein et al.
which reported 5-year survival rate of 18.4%37.
RFA is often compared to percutaneous ethanol injec-
tion which is one modality that has also been used to
treat unresectable liver malignancy in some institutions.
Studies have shown that 4 to five 5 sessions per tumor
need to be performed to achieve complete necrosis in 80%
of tumors. The mean total procedure time for each ses-
sion was approximately 30 minutes38–40. Our study dem-
onstrates that treatment with RF ablation can result in
complete tumor necrosis in about 90% of patients which
is higher than that could be achieved with PEI. An addi-
tional and important advantage of RFA over PEI is that
fewer treatment sessions were required to achieve this
result. Therefore, RF ablation is preferred treatment for
patients with unresectable hepatic malignancy where
such option is available. In case where RFA gadget is not
available PEI is an adequate replacement. The similar
results could be accomplished at much lower cost.
We could not compare the survival rate using RFA
and patients with unresectable hepatic disease left with-
out treatment, because methodologically it is very diffi-
cult to find case controls, but 42% 2-year survival rate is
very satisfactory for patients with unresectable hepatic
malignancy and is similar to other studies41,42 as is 5-year
survival rate of 8.3%37. Natural history of unresectable
primary HCC is measured in weeks (range 7.6–16.6) de-
pending on the tumor stage43. Systemic chemotherapy
was administered according to the type of tumor. Meta-
static hepatic disease from colorectal origin was treated
with oxaliplatine and/or irinotecan.
RFA seems to be safe and effective treatment tech-
nique for patients with unresectable hepatic malignan-
cies smaller than 5 cm and without distant metastatic
disease. This conclusion will change with further devel-
opment of RFA equipment with possibilities of ablation
of larger lesions. RF ablation results in complete necrosis
in 80–90% with 2-year and 5-year survival rate of 42%
and 8% respectively which is much higher that without
treatment when survival is measured in weeks42 and
months or with chemotherapy alone when median sur-
vival is 20 months44. It must be always offered to patients
with unresectable disease as treatment of choice when
indicated. If this modality is unavailable, percutaneous
ethanol injection can be done, with two disadvantages:
the results are inferior and PEI requires more treatment
sessions than RFA (with higher possibility of intra- and
postoperative complications), but is a safer procedure in
inexperienced hands.
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RADIOFREKVENCIJSKA ABLACIJA KAO LOKALNO-REGIONALNA TERAPIJA
NERESEKTABILNIH HEPATALNIH METASTAZA: PO^ETNI REZULTATI KOD
24 BOLESNIKA TIJEKOM 5-GODI[NJEG PRA]ENJA
S A @ E T A K
Radiofrekvencijska ablacija (RFA) jedan je terapijski modalitet za lije~enje neresektabilnih jetrenih metastaza. Bo-
lesnici sa jetrenim metastazama (n=24) podvrgnuti su elektivnoj RFA. Ablacija svih jetrenih metastaza vr{ena je u
svrhu izlije~enja (kurativno) sa 1 cm zdravog ruba tijekom jedne (jedine) operacije. Srednji promjer tumora iznosio je
3,1 cm (rang 1,7–6,9 cm). Bolesnici podvrgnuti zahvatu nisu bili kandidati za resekcijski zahvat zbog: multifokalnih
jetrenih metastaza, ekstrahepatalne pro{irenosti bolesti, blizine velikih krvnih `ila ili prisutne ciroze sa nedovoljnom
hepatalnom rezervom koja bi preostala nakon resekcije. Kompletna tumorska nekroza postignuta je u 87,5%, a rek-
urencija tumora pojavila se u 3 (12,5%) bolesnika i to kod metastatskih lezija ve}ih od 5 cm. Udaljena intrahepatalna
rekurencija dijagnosticirana je u 4 bolesnika (16,7%). Udaljene metastaze verificirane su u 7 (29,2%) bolesnika. Kod 4
od tih 7 bolesnika tako|er je bila prisutna i udaljena intrahepatalna rekurencija bolesti. Dvogodi{nje i 5-godi{nje stope
pre`ivljenja iznosile su 41,7% (10 bolesnika) i 8,3% (2 bolesnika). Tijekom 24 mjeseca pra}enja, pre`ivljenje je iznosilo
41,7% (10 bolesnika). RFA je sigurna i efikasna metoda kod bolesnika sa neresektabilnim hepatalnim metastazama
manjim od 5 cm bez udaljene metastatske bolesti. RFA je rezultirala sa kompletnom tumorskom nekrozom u 87,5%
slu~ajeva sa 2- i 5-godi{njim stopama pre`ivljenja znatno du`im u odnosu na primjenu isklju~ivo kemoterapije ili supor-
tivne terapije kada se pre`ivljenje mjeri u tjednima ili mjesecima. Ako RFA nije dostupna tako|er je mogu}e primjeniti
perkutanu instlaciju etanola koja daje ipak lo{ije rezultate.
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